eli lilly retatrutide trial results New obesity drug dubbed 'triple G' appears even more powerful than Wegovy - shedding 25% bodyweight eli lilly retatrutide lawsuit The

a low dose which need not be an independently therapeutically effective amount of a PDE-5 inhibitor a low dose which need not independently be a therapeutically effective amount of a melanocortin agonist

Their approach to Ozempic coverage in 2026 is not uniform

Food and Drug Administration announced a Green List import alert to help stop potentially dangerous GLP-1 active pharmaceutical ingredients (APIs) from unverified foreign sources from entering the U.S

Anti-aging enthusiasts UV damage is the #1 driver of skin aging

This tumor can grow around the eye but rarely spreads to other parts of the body

New research tools for urogenital schistosomiasis